Cefixim Alkaloid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefixim Alkaloid

Property Description
Active ingredient Cefixime (often as trihydrate)
Form Tablet, Capsule, Oral Suspension
Pharmacological class Third-generation Cephalosporin, beta-lactam Antimicrobial
Common use Systemic bacterial infections
Origin Semisynthetic

The preparation known as Cefixim Alkaloid is a prescription-only medication whose active component is Cefixime, a potent agent used to treat systemic bacterial disease. It is formally classified as a beta-lactam antimicrobial, specifically designated as a third-generation cephalosporin antibiotic. This classification confirms that Cefixime belongs to a modern group of antibiotics whose efficacy against common infections is widely clinically recognized. Its inclusion on the WHO Essential Medicines List underscores its importance as a critical broad-spectrum therapeutic agent. Popular brand names containing this same active ingredient include Suprax, Cefspan, and Fixacef.


Composition, Origin, and Available Forms

The medication is a single-ingredient product, containing only Cefixime (commonly as Cefixime trihydrate) as the active substance, an agent derived from semisynthetic, synthetic organic processes. Cefixime distinguishes itself within its class by being one of the few cephalosporins that are highly orally-active, making it a versatile choice for outpatient therapy. Cefixime is administered via the oral route and is supplied in various pharmaceutical preparations, including the solid forms of tablet and capsule, alongside a liquid oral suspension, making it suitable for both adults and pediatric patient groups.


General Purpose and Mechanism Summary

The primary general purpose of Cefixime is to resolve illness by acting as a strong bactericidal agent, meaning it actively kills susceptible bacteria within the body. Cefixime achieves this through its beta-lactam structure, which fundamentally disrupts the ability of bacteria to correctly build and maintain their essential protective outer layer, the cell wall. This targeted action makes Cefixime a highly effective tool for systemic management, providing a necessary and robust solution for clearing infections and restoring health.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Cefixim Alkaloid?

Possible Side Effects and Safety Information

Cefixim Alkaloid (cefixime) is an antibacterial agent of the cephalosporin class. Its safety profile is based on clinical trials and post-marketing surveillance, establishing a set of common and serious adverse reactions.

Common and Serious Adverse Reactions

The most frequently reported side effects involve the Gastrointestinal System, primarily diarrhea (including loose or frequent stools) and nausea, which are often mild. Other common but less frequent reactions may include abdominal pain, dyspepsia, and headache.

Serious and Clinically Significant Reactions

  • Hypersensitivity Reactions: Severe allergic reactions, including anaphylaxis, angioedema, and serious skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Immediate medical attention is required for signs of severe allergy, like rash, hives, swelling of the face/throat, or difficulty breathing.
  • Clostridium difficile-associated diarrhea (CDAD): This condition, which may range from mild diarrhea to fatal colitis, has been reported with nearly all antibacterial agents, including cefixime. Bloody or watery diarrhea, or persistent diarrhea, requires prompt evaluation.
  • Hepatic and Renal Effects: Liver enzyme elevations (transient) and, rarely, severe adverse events like acute renal failure or immune-mediated hemolytic anemia have been noted. Seizures have also been reported, particularly in patients with pre-existing renal impairment where the dosage was not appropriately adjusted.

Safety Considerations and Contraindications

Cefixim Alkaloid is contraindicated in patients with a known allergy to cefixime or to any antibiotic in the cephalosporin class. Caution is advised for patients with a history of penicillin allergy due to the potential for cross-hypersensitivity. Dose adjustments are required for patients with significant renal impairment (creatinine clearance <60 mL/min). The safety and efficacy of the drug have not been established in pediatric patients under six months of age. Caution is also necessary when the drug is used concomitantly with anticoagulants (like warfarin) due to an increased risk of bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Cefixim Alkaloid is primarily associated with the risk of severe neurotoxicity, a documented concern for the cephalosporin class of antibiotics. Officially reported clinical manifestations include signs of encephalopathy, which may present as confusion, impairment of consciousness, movement disorders, and convulsion. The most serious documented outcome is the potential for generalized seizures.

Emergency Action and Required Management

Regulatory guidance states that emergency medical attention must be sought immediately if an overdose is suspected, or upon the onset of severe CNS symptoms. If seizures occur, the official documentation mandates that the drug must be discontinued.

In cases of overdose, no specific antidote exists. Management is therefore restricted to general symptomatic and supportive measures. Gastric lavage may be indicated as an official initial procedure. A key procedural note is that Cefixime is not removed from the circulation in significant quantities by dialysis. This neurotoxicity risk is specifically heightened for patients with renal impairment, emphasizing a need for careful monitoring in this population.

Therapeutic Uses of Cefixim Alkaloid

Cefixim Alkaloid is commonly used for managing systemic infections caused by susceptible bacteria. Its use may support symptomatic relief by addressing symptoms associated with acute and often distressing manifestations. The medication is generally applied across several core therapeutic domains.


Managing Acute Respiratory and Ear Symptoms

This medication is commonly applied to address bacterial infections resulting in pronounced inflammation in the respiratory tract and middle ear. It is used in conditions such as acute otitis media, pharyngitis, and tonsillitis, and for the management of acute exacerbations of chronic bronchitis. This may contribute to easing the overall symptom load, relevant for managing symptoms like ear pain, sore throat, and infectious cough that interfere with daily functioning.


Therapeutic Support for Urinary and Systemic Infections

Cefixime is considered relevant in clinical settings marked by infections of the genitourinary system, such as uncomplicated urinary tract infections (UTIs), as well as specific systemic illnesses like Typhoid fever. A main benefit is easing the overall symptom burden, which may assist with managing symptoms related to physical discomfort like painful urination (dysuria) and systemic imbalance like high fever and malaise.


Quick Fact: Relief for Systemic Discomfort

The medication may support the patient during difficult episodes by easing distress in conditions presenting with systemic or localized discomfort, particularly in acute episodes of UTIs and respiratory infection exacerbations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefixim Alkaloid?

The population eligibility for Cefixim Alkaloid (Cefixime) is strictly defined by regulatory documents, focusing on hypersensitivity status, age, and organ function.


Contraindicated Populations

Cefixim Alkaloid is contraindicated in patients with a known hypersensitivity to Cefixime itself, any excipient, or to any other cephalosporin or beta-lactam antibacterial agent (such as penicillins). This prohibition is based on the documented risk of severe cross-hypersensitivity reactions.


Age and Organ Function Restrictions

Population Group Official Eligibility Status
Adults and Children Use is established for patients six months of age and older.
Infants (< 6 months) Safety and efficacy have not been established, and use is not recommended.
Renal Impairment Use is conditional for patients with impaired renal function (Creatinine Clearance < 60 mL/min), requiring close monitoring and specific dosage adjustment.
Pregnancy Use is permitted only if clearly needed (Category B) due to insufficient human study data.
Lactation Use is restricted; official labeling recommends considering temporary discontinuation of nursing during treatment.

Additional Conditional Use

Patients with a history of penicillin allergy or gastrointestinal disease, particularly colitis, are advised to use the medicine with caution due to specific documented risks. Additionally, the chewable tablet form is restricted for patients with Phenylketonuria (PKU) as it contains phenylalanine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

When Cefixim Alkaloid is taken alongside certain other medications, the effects of those medicines may be altered. It is important to inform a healthcare provider of all prescription, over-the-counter, and herbal products being used.

Anticoagulants (Blood Thinners)

Co-administration with blood thinners, particularly Warfarin and related agents, can increase the risk of bleeding. Cefixime has been associated with a prolongation of prothrombin time (PT), an effect that measures how quickly blood clots. This prolongation indicates a heightened effect of the anticoagulant. Patients taking Warfarin must have their blood clotting levels closely monitored, and dosage adjustments may be necessary.

Carbamazepine

Concurrent use of Cefixime and the anticonvulsant medicine Carbamazepine may lead to elevated Carbamazepine plasma levels. If these medicines are taken together, monitoring the Carbamazepine concentration in the blood may be helpful to ensure levels remain within a safe and effective range.

Drug/Laboratory Test Interactions

Cefixime may affect the results of certain medical tests. Specifically, it can lead to a false-positive reaction for glucose in the urine when tests based on Benedict’s or Fehling’s solutions are used. It is recommended to use glucose tests based on enzymatic methods while taking this medication. Additionally, a false-positive direct Coombs test has been reported with other medicines in the cephalosporin class.

Mechanism of Action

How Cefixim Alkaloid Works

Cefixime operates via a bactericidal mechanism, selectively causing the death of susceptible bacteria by targeting an essential structure unique to the microbial cell. This process is initiated by the molecular action of the drug as an irreversible inhibitor.

Molecular Targeting of Essential Bacterial Enzymes

The primary biological targets are Penicillin-Binding Proteins (PBPs), specifically the D,D-transpeptidases, located on the bacterial inner membrane. Cefixime forms a stable, covalent bond with the active site of these enzymes, immediately neutralizing their function. This molecular interaction begins the destructive cascade by halting enzyme activity required for structural maintenance.

Causal Cascade: Structural Failure and Lysis

The inactivation of PBPs directly blocks the final cross-linking step of peptidoglycan synthesis, which is critical for constructing the rigid bacterial cell wall. This structural compromise leads to a loss of the cell's osmotic integrity and often triggers the uncontrolled activation of the bacteria's own autolytic enzymes.

Resulting Physiological Effect: Pathogen Lysis

This combined effect of cell wall assembly inhibition and subsequent autolysis results in the rupture and lysis of the susceptible microbial cell. This definitive bactericidal action (destruction of the pathogen) is the sole physiological consequence produced by the Cefixime mechanism.

Dosage and Administration Information

How to Use Cefixim Alkaloid

Cefixim Alkaloid, which contains the active ingredient Cefixime, is used according to specific, label-based administration protocols. The medication is designated for oral use only in all approved forms, which include capsules, film-coated tablets, chewable tablets, and a powder for oral suspension.


Dosing and Frequency Patterns

The standard adult daily dose is 400 mg. This may be administered as a single 400 mg dose once daily, or it may be divided and taken as 200 mg every 12 hours. The regimen for specific infections, such as uncomplicated gonorrhea, is a single 400 mg dose. The treatment course typically lasts 7 to 14 days, though it must be maintained for a minimum of 10 days when treating infections involving Streptococcus pyogenes.


Administration Contexts

Contextual Rule Official Instruction
Timing Relative to Food May be administered without regard to food (with or without meals).
Suspension Handling The powder must be reconstituted with water and shaken well before each use.
Otitis Media Constraint The tablet/capsule form is not interchangeable with the suspension for the treatment of otitis media.

Population-Specific Use

Dosing modifications are required for certain patient groups. For children starting at six months of age, the dose is calculated based on body weight at 8 mg/kg/day, which is often administered via the oral suspension. Dosing must be adjusted for adults with renal impairment; for those with severe impairment (CrCl le 20 mL/min), the dose is typically reduced to a maximum of 200 mg once daily. Infants younger than six months are not included in the established safety and efficacy data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefixim Alkaloid

The clinical evaluation of Cefixim Alkaloid is based on research evidence described in regulatory submissions and scientific literature. This overview describes the types of studies that have been conducted, the outcomes they monitored, and the acknowledged gaps in the current evidence landscape, strictly without offering medical advice or treatment recommendations.


Evidence for Uncomplicated Urinary Tract Infections (UTIs)

Research exploring Cefixime for conditions characterized by functional limitations, such as uncomplicated UTIs, primarily consists of regulatory reviews summarizing previously conducted prospective, randomized trials. Researchers examined two primary outcome measures: Bacteriological Outcome (monitoring the clearance of the specific bacteria) and Clinical Outcome (observing how symptoms evolved in the study populations). These studies were conducted across both adult and pediatric patient groups. The evidence base used for regulatory conclusions for this indication was assigned a classification of High.

What remains uncertain is the reliance on older data; recent regulatory files noted that clinical efficacy conclusions relied upon older findings from the reference listed drug. Consequently, long-term effects are not fully established, and there is limited information for outcomes related to potential recurrence beyond the defined time intervals of the acute trials.


Evidence for Acute Respiratory and Ear Infections (AOM, Pharyngitis, Tonsillitis, AECB)

Studies were conducted during periods of increased symptom activity in the pediatric population for Acute Otitis Media (AOM), and in adults for pharyngitis, tonsillitis, and acute flare-ups of chronic bronchitis (AECB). In all cases, the studies explored Clinical Outcome by monitoring the evolution of the acute, disruptive episodic symptoms in the observed populations. The evidence base used for regulatory conclusions for these conditions was assigned a classification of High.

Regulatory conclusions rely on studies that were previously conducted for the reference listed drug. Data describing extended follow-up outcomes, such as rates of symptom recurrence, are not well characterized in publicly available summaries, suggesting that long-term effects are not fully established.


Evidence for Uncomplicated Gonococcal Infections

This indication has been studied for conditions characterized by episodic manifestations using Randomized Controlled Trials (RCTs), as well as Systematic Reviews and Meta-analyses. Ongoing surveillance studies monitor trends related to antimicrobial resistance.

Research examined two main outcomes: Microbiological Outcome (monitoring the clearance of the specific causative bacteria) and Clinical Response (tracking changes in patient-reported outcomes). Findings describe patterns observed in these studies, but the evidence quality varies across them. Some systematic reviews identified a high risk of bias in the original primary RCTs, leading to an overall classification of the evidence base as Moderate.

Frequently Asked Questions (FAQ)

Common questions about Cefixim Alkaloid (FAQ)


Q: How quickly should I expect Cefixim Alkaloid to start working?

A: Official information indicates that people may begin to feel better during the first few days of taking the medication. The active ingredient typically reaches its highest concentrations in the bloodstream approximately 2 to 6 hours after administration.


Q: Does Cefixim Alkaloid interact with birth control pills?

A: Studies and regulatory documents suggest that, like some other antibiotics, Cefixim Alkaloid may potentially reduce the effectiveness of oral contraceptives that contain ethinyl estradiol. This may theoretically lead to reduced efficacy of the contraceptive.


Q: Can I take Cefixim Alkaloid if I'm allergic to amoxicillin?

A: Official safety information notes that Cefixim Alkaloid is contraindicated (should not be used) if an individual is allergic to the cephalosporin class of antibiotics. Due to the potential for similar reactions, individuals with a history of penicillin-class medicines, such as amoxicillin, have a documented need for use with caution due to the potential for cross-hypersensitivity reactions.


Q: What happens if I miss a dose of Cefixim Alkaloid?

A: If a dose is missed, regulatory guidance is to take it as soon as it is remembered. However, if the time is almost right for the next scheduled dose, the missed dose should be skipped entirely. Regulatory guidance advises against taking a double dose to compensate.


Q: Does Cefixim Alkaloid make you drowsy or tired?

A: While the active ingredient is not consistently listed as causing drowsiness or fatigue, official safety documents do include dizziness and headache among the less common side effects reported. These effects, if experienced, may influence attention or coordination.


Q: Can Cefixim Alkaloid cause a yeast infection?

A: Official patient information notes that taking Cefixim Alkaloid, similar to other antibiotics, may sometimes result in an overgrowth of organisms that are not affected by the medication. This shift may promote the overgrowth of organisms not susceptible to the medication, sometimes resulting in symptoms such as itching or discharge.


Q: Does taking Cefixim Alkaloid affect my ability to drive?

A: Official documents list side effects like dizziness and headache in their safety profiles. Individuals should be aware that these symptoms, if they occur, may affect attention or coordination.


Q: Are there different forms of Cefixim Alkaloid, like liquid or tablets?

A: Yes, Cefixim Alkaloid is available in several forms for oral use, including capsules, tablets, chewable tablets, and a powder for oral suspension (liquid form). Official guidance specifies that the tablets and the suspension are not interchangeable for treating certain conditions.


Q: Is it normal to have a change in taste while on Cefixim Alkaloid?

A: While a change in taste is not frequently listed among the main adverse effects in regulatory documents, the active ingredient itself is known to have a naturally bitter taste. This characteristic has led manufacturers to use special formulation techniques for liquid and chewable products to help mask the taste.


Q: What if Cefixim Alkaloid doesn't seem to be working for my condition?

A: Official patient guidance recommends that if symptoms do not start to improve or if they appear to get worse during the first few days of treatment, official guidance recommends contacting a healthcare provider.


Q: Does food affect how Cefixim Alkaloid is absorbed?

A: Pharmacokinetic data from regulatory files indicate that Cefixim Alkaloid can be taken with or without food. While taking it with food may slightly delay the time it takes to reach maximum concentration in the blood, the total amount of medicine absorbed by the body is not significantly changed.


Q: Are there any common misuses of Cefixim Alkaloid that people should avoid?

A: Official warnings clarify that the medicine is not for use in viral infections, such as the common cold, because its function is limited to bacteria. Individuals are also cautioned that stopping the full course of medicine too early can lead to treatment failure and increase the risk of antibiotic resistance.


Q: Can older adults use Cefixim Alkaloid safely?

A: Official information notes that concentrations of the active ingredient in the blood are generally higher in elderly patients compared to younger adults. The most important factor in use for older adults is the patient's kidney function, which requires close monitoring and potential dosage adjustment for appropriate use in this population.


Q: What does the research say about Cefixim Alkaloid use in breastfeeding mothers?

A: Official regulatory documents indicate that it is not known if the active ingredient is excreted into human breast milk. Due to theoretical concerns, official product labeling often states that the decision to continue or discontinue nursing should be considered during treatment.


Q: Are there any specific laboratory tests that Cefixim Alkaloid can interfere with?

A: Yes, official drug information notes that Cefixim Alkaloid can interfere with the results of certain medical tests. It may cause a false-positive reaction for glucose in the urine if specific testing solutions are used. It may also lead to a blood test result known as a false-positive direct Coombs test.


Q: Why is the full course of Cefixim Alkaloid necessary even after symptoms disappear?

A: Official patient guidance emphasizes that the full prescribed course should be completed, even if symptom relief occurs early. This is necessary to ensure that all of the bacteria causing the infection have been cleared, which helps prevent the return of the infection and reduces the risk of developing drug-resistant bacteria.


Q: What are the main things users commonly misunderstand about Cefixim Alkaloid?

A: Official patient guidance focuses on clarifying that the medication only works for bacterial infections, not viral ones like a cold or flu. It is also important to understand that not finishing the full prescribed course is a common error that can compromise treatment success and contribute to antibiotic resistance.


Q: Is it common for Cefixim Alkaloid to be prescribed as a single dose?

A: Official regulatory prescribing information confirms that a single dose of 400 mg is the established regimen for the treatment of uncomplicated gonorrhea. For most other approved infections, the typical regimen involves a longer course of treatment that lasts 7 to 14 days.


Q: Is Cefixim Alkaloid described as a first-line treatment for any specific condition?

A: Official documents note that for infections like pharyngitis or tonsillitis caused by Streptococcus pyogenes, a different antibiotic (Penicillin) is typically considered the standard of choice. However, Cefixim Alkaloid is included on the WHO Essential Medicines List and is recognized as an important broad-spectrum agent.


Q: Does Cefixim Alkaloid interact with blood thinning medications like warfarin?

A: Official interaction information states that co-administration with blood thinning agents, such as Warfarin, can cause a heightened effect of the anticoagulant. This interaction may be associated with an increased risk of bleeding, and official information notes that patient monitoring may be necessary when both medicines are used.

How should Cefixim Alkaloid be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines strict conditions for storing Cefixime based on the formulation.

Storage Conditions

Formulation Required Temperature Additional Protection
Capsules/Tablets Controlled Room Temperature (20 C to 25 C) Protect from moisture and excessive heat.
Liquid Suspension Room Temperature (up to 25 C) OR Refrigerated (2 C to 8 C) Must not be frozen.

All forms must be stored in a tightly closed container and kept out of the reach of children.

Stability and Disposal

The reconstituted liquid suspension is stable for 14 days; any unused portion must be discarded after this period. Expired or unused medication must not be thrown into household trash or wastewater. Disposal should follow regulatory guidelines, and patients must ask a healthcare professional or pharmacist for proper instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefixim Alkaloid found in:

A-Z Index: